Logotype for Krsnaa Diagnostics Limited

Krsnaa Diagnostics (KRSNAA) Q2 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Krsnaa Diagnostics Limited

Q2 2025 earnings summary

8 Jul, 2026

Executive summary

  • Achieved strong growth in Q2 and H1 FY2025, driven by operational efficiency, increased patient footfalls, new project wins, and strategic investments in high-growth healthcare sectors such as oncology and cardiac care.

  • Expanded geographic footprint to 150+ districts across 18 states/UTs, with major contracts in Jharkhand, Assam, Maharashtra, Madhya Pradesh, and Odisha, including 45 new radiology centers, one pathology lab, and 731 collection centers.

  • Entered strategic partnerships with United Imaging and Medikabazaar to enhance diagnostic capabilities and expand into Tier 2 and Tier 3 cities, with plans for 30+ imaging and pathology centers and favorable financing terms.

  • Strategic investment in Apulki Healthcare for exclusive oncology and cardiac diagnostics partnership, securing a 30-year contract and long-term revenue visibility.

  • Focused on asset-light, technology-enabled expansion and a patient-centric retail strategy to diversify revenue streams.

Financial highlights

  • Q2 FY2025 consolidated revenue reached ₹1,863.40 million, up 20% year-on-year; H1 FY2025 consolidated revenue at ₹3,565.72 million, up 21% year-on-year.

  • Q2 EBITDA was ₹509 million, up 58% year-on-year; H1 EBITDA at ₹951 million, up 48% year-on-year.

  • Q2 PAT stood at ₹195.96 million, up 87% year-on-year; H1 PAT at ₹375.17 million, up 49% year-on-year.

  • Maintained net debt-free status with cash and equivalents of ₹112.79 million as of September 2024.

  • Receivables at ₹243 crores, with ₹125 crores from two states; company expects receivable days to normalize to 90 by year-end.

Outlook and guidance

  • Confident in achieving 25% revenue growth for FY2025, with sustainable EBITDA margins above previous guidance.

  • Guidance for CapEx remains at ₹1,700 million for FY2025.

  • Margins expected to remain stable, supported by operational efficiencies and cost-saving initiatives.

  • Focus on tapping underpenetrated diagnostic markets via new PPP tenders and expanding retail presence.

  • Plans to leverage digital marketing, process automation, and cost control for sustained profitability.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more